Should patients stop taking aspirin for primary prevention?

Jeremiah P. Depta, MD, MPHS
Jeremiah P. Depta
Brigham and Women’s Hospital Heart and Vascular Center; Harvard Medical School, Boston, MA
MD, MPHS
and Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
Deepak L. Bhatt
Executive Director of Interventional Cardiovascular Programs, Brigham and Women’s Hospital Heart and Vascular Center; Professor of Medicine, Harvard Medical School, Boston, MA
MD, MPH, FACC, FAHA, FSCAI, FESC
- Find this author on Google Scholar
- Find this author on PubMed
- Search for this author on this site
- For correspondence: [email protected]

This is a PDF-only article. The first page of the PDF of this article appears above.

Footnotes

↵* Dr. Bhatt has disclosed the following relationships: Advisory Board: Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care; Chair: American Heart Association Get With the Guidelines Steering Committee; Data Monitoring Committees: Duke Clinical Research Institute, Harvard Clinical Research Institute, Mayo Clinic, Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials, and News, ACC.org), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), Harvard Clinical Research Institute (clinical trial steering committee), HMP Communications (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Associate Editor; Section Editor, Pharmacology), Population Health Research Institute (clinical trial steering committee), Slack Publications (Chief Medical Editor, Cardiology Today’s Intervention), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor); Research funding: Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Forest Laboratories, Ischemix, Medtronic, Pfizer, Roche, Sanofi Aventis, The Medicines Company; Unfunded Research: FlowCo, PLx Pharma, Takeda.

PDF